Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Apr 1;9(4):570-571.
doi: 10.1001/jamaoncol.2022.7589.

Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade-Reply

Biagio Ricciuti  1 , Xinan Wang  2 , Mark M Awad  1
Affiliations
Comment

Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade-Reply

Biagio Ricciuti et al. JAMA Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Ricciuti reported serving on an advisory board for Regeneron outside the submitted work. Dr Awad reported grants from Lilly, Amgen, Bristol Myers Squibb, AstraZeneca, and Genentech and personal fees from Genentech, Bristol Myers Squibb, Merck, AstraZeneca, Blueprint Medicine, Gritstone, ArcherDx, Nektar, Novartis, Mirati, EMD Serono, and Iovance outside the submitted work. No other disclosures were reported.

Comment on

References

    1. Ricciuti B, Wang X, Alessi JV, et al. Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol. 2022;8(8):1160–1168. doi:10.1001/jamaoncol.2022.1981 - DOI - PMC - PubMed
    1. Yoneda K, Kuwata T, Kanayama M, et al. Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer. Br J Cancer. 2019;121(6):490–496. doi:10.1038/s41416-019-0541-3 - DOI - PMC - PubMed
    1. Shin J, Chung J-H, Kim SH, et al. Effect of platinum-based chemotherapy on PD-L1 expression on tumor cells in non-small cell lung cancer. Cancer Res Treat. 2019;51(3):1086–1097. doi:10.4143/crt.2018.537 - DOI - PMC - PubMed
    1. Lamberti G, Spurr LFF, Li Y, et al. Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer. Ann Oncol. 2020;31(6):807–814. doi:10.1016/j.annonc.2020.02.017 - DOI - PubMed
    1. Lisberg A, Cummings A, Goldman JW, et al. A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC. J Thorac Oncol. 2018;13(8):1138–1145. doi:10.1016/j.jtho.2018.03.035 - DOI - PMC - PubMed

MeSH terms